Table 2.
Serum Lipid Profile of Breast Cancer and Healthy Women
| Test (Reference range- mg/dL) | Breast cancer patients without CLD (n= 126) | Breast cancer patients with CLD (n= 29) | Healthy females (n= 75) | |||
|---|---|---|---|---|---|---|
| Pre (n=50) | Post (n=76) | Pre (n=8) | Post (n= 21) | Pre (n=30) | Post (n=45) | |
| 1TC (< 200) | 226±40a | 231±48a | 167±43b | 203±63c | 178±23b | 194±19b |
| 1LDL-C (< 100) | 158±34c | 161±44c | 100±37d | 133±52d | 111±23d | 114±23d |
| 1HDL-C (> 40) | 43±10e | 42±12e | 43±7.7e | 45±12e | 44±8.3e | 45±7.2e |
| 1TG (<150) | 122±58f | 139±64f | 117±71f | 122±74f | 108±45f | 123±13f |
| 1TC:HDL-C (< 5) | 5.5±1.4g | 5.8±1.8g | 3.9±1.2h | 4.8±1.8h | 4.2±0.9h | 4.2±0.7h |
CLD, Cholesterol lowering drugs; Pre, Premenopausal; Post, Postmenopausal; TC, Total Cholesterol; LDL-C, Low Density Lipoprotein Cholesterol; HDL-C, High density lipoprotein cholesterol; TG, Triglycerides; TC:HDL-C, Total cholesterol: high density lipoprotein cholesterol; 1Third Report of the National Cholesterol Education Programme (Adult Treatment Panel III), 2002; Different superscripts along a row indicate significant differences at 95% confidence interval.